-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 6c
-
-
-
-
-
-
-
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Tops Q1 EPS by 3c
-
-
-
-
-
-
-
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
-
-
-
-
-
-
-
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

